Cargando…

Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody

Bispecific antibodies (BsAbs) have proven highly efficient T cell recruiters for cancer immunotherapy by virtue of one tumor antigen-reactive single chain variable fragment (scFv) and another that binds CD3. In order to enhance the antitumor potency of these tandem scFv BsAbs (tsc-BsAbs), we exploit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmed, Mahiuddin, Cheng, Ming, Cheung, Irene Y, Cheung, Nai-Kong V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485828/ https://www.ncbi.nlm.nih.gov/pubmed/26137406 http://dx.doi.org/10.4161/2162402X.2014.989776

Ejemplares similares

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2021)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2
por: Ahmed, Mahiuddin, et al.
Publicado: (2014)

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response
por: Park, Jeong A., et al.
Publicado: (2021)

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
por: Park, Jeong A, et al.
Publicado: (2022)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
por: Ahmed, Mahiuddin, et al.
Publicado: (2013)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
por: Park, Jeong A, et al.
Publicado: (2021)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
por: Passariello, Margherita, et al.
Publicado: (2019)

Construction and expression of D-dimer and GPIIb/IIIa single-chain bispecific antibody
por: DAN, ZHAOKUI, et al.
Publicado: (2013)

Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models
por: Warwas, Karsten M., et al.
Publicado: (2021)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy
por: Song, Xinxin, et al.
Publicado: (2022)

Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
por: Lim, Shion A., et al.
Publicado: (2021)

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
por: Trinklein, Nathan D., et al.
Publicado: (2019)

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
por: Lutz, Sebastian, et al.
Publicado: (2023)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
por: Weth, R, et al.
Publicado: (2004)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6
por: Moshoette, Tumelo, et al.
Publicado: (2022)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells
por: Huang, Shuyu, et al.
Publicado: (2022)

Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
por: Ku, Zhiqiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_82vb9a9rpm4ta6djggihg9p3cf